Optimizing HSCT in Blood Cancers

Optimizing HSCT in Blood Cancers

From Treating Blood Cancers by Blood Cancer United

June 2, 2026 · 39 min

About this episode

Dr. Lori Muffly discusses the role of HSCT in blood cancer treatment and recent advances in the field.

Lori Muffly MD, MS, Stanford Medicine, Stanford, CA Recorded on May 12, 2026 Lori Muffly MD, MS Professor of Medicine Division of Blood and Marrow Transplantation & Cellular Therapy Stanford Medicine Stanford, CA In this episode, Dr. Lori Muffly from Stanford Medicine explores how hematopoietic stem cell transplantation (HSCT) continues to play a central role in care, even as cellular therapies evolve. She also discusses recent advances in overall survival and graft versus host disease as well as clinical trials. We also explore barriers to access, the importance of multidisciplinary teams, and resources to support patients and healthcare professionals. Join us for this insightful episode on the important role of HSCT today, and where it’s headed next. Mentioned on this episode: www.NMDP.org www.hematology.org Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients

People in this episode

Guest: Lori Muffly MD, MS

Topics covered

  • hematopoietic stem cell transplantation
  • blood cancers
  • cellular therapies
  • clinical trials
  • graft versus host disease
  • multidisciplinary teams

Keywords

  • HSCT
  • blood cancers
  • cellular therapies
  • graft versus host disease
  • clinical trials
  • patient resources

Mentioned in this episode

Organizations: Stanford Medicine, NMDP, hematology.org, Blood Cancer United

More episodes of Treating Blood Cancers

Explore listener stats, chart rankings, contacts and more on the Treating Blood Cancers podcast page.